

Commission Regulation (EEC) No 2061/89 of 7 July 1989 concerning
the classification of certain goods in the combined nomenclature

COMMISSION REGULATION (EEC) No 2061/89
of 7 July 1989

concerning the classification of certain goods in the combined nomenclature

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community,

Having regard to Council Regulation (EEC) No 2658/87⁽¹⁾ on the tariff and statistical nomenclature and on the Common Customs Tariff, as last amended by Regulation (EEC) No 1672/89⁽²⁾, and in particular Article 9 thereof,

Whereas in order to ensure uniform application of the combined nomenclature annexed to Regulation 2658/87, it is necessary to adopt measures concerning the classification of the goods referred to in the Annex to this Regulation;

Whereas Regulation (EEC) No 2658/87 has set down the general rules for the interpretation of the combined nomenclature and these rules also apply to any other nomenclature which is wholly or partly based on it or which adds any additional subdivisions to it and which is established by specific Community provisions, with a view to the application of tariff or other measures relating to trade in goods;

Whereas, pursuant to the said general rules, the goods described in column 1 of the table annexed to the present Regulation must be classified under the appropriate CN codes indicated in column 2, by virtue of the reasons set out in column 3;

Whereas the measures provided for in this Regulation, are in accordance with the opinion of the nomenclature Committee,

HAS ADOPTED THIS REGULATION:

Article 1

The goods described in column 1 of the annexed table are now classified within the combined nomenclature under the appropriate CN codes indicated in column 2 of the said table.

Article 2

This Regulation shall enter into force on the 21st day following its publication in the *Official Journal of the European Communities*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EEC) No 2061/89. (See end of Document for details)

ANNEX

Description of the goods (1)	Classification (CN code) (2)	Reasons (3)
<p>1. Preparation in the form of tablets put up in packings for retail sale with instructions on dosage and composition to counter deficiency resulting from food lacking in proteins.</p> <p>Composition per 100 g of the preparation:</p> <ul style="list-style-type: none"> — L-histidine: 4,2 g — L-isoleucine: 4,2 g — L-leucine: 4,2 g — L-lysine: 4,2 g — L-methionine: 4,2 g — L-phenylalanine: 4,2 g — L-threonine: 4,2 g — L-tryptophan: 4,2 g — L-valine: 4,2 g — L-cystine: 2,8 g — L-glycine: 2,8 g — L-cysteïn: 2,8 g — L-tyrosine: 2,8 g — L-aurine: 2,8 g — L-arginine: 2,8 g — L-ornithine: 2,8 g — L-glutamine: 2,8 g — L-alanine: 1,4 g — L-aspartic acid: 1,4 g — L-glutamic acid: 1,4 g — L-citruline: 1,4 g — L-serine: 1,4 g — L-proline: 1,4 g — L-glutathion: 1,4 g — L-carnitine: 1,4 g — Cellulose, stearic acid, magnesium stearate, silicon dioxide and food glaze containing protein: ad 100 g 	<p>[^{F1}2106 90 92]</p>	<p>Classification is determined by the provisions of general rules 1 and 6 for the interpretation of the combined nomenclature and the texts of CN codes 2106, 2106 90 and [^{F1}2106 90 92]. The products is a food supplement (see also HS Explanatory [^{F2}Note to heading 21.06])</p>

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EEC) No 2061/89. (See end of Document for details)

<p>2. Preparation in the form of tablets put up in packings for retail sale with instructions on dosage and composition to counter, in particular, deficiency resulting from the growth of children.</p> <p>Composition per 100 g of the preparation:</p> <ul style="list-style-type: none"> — glycine: 36,2 g — L-ornithine: 27,2 g — L-tryptophan: 9,1 g — Niacinamide: 2,2 g — Vitamin B6: 0,8 g; — Cellulose, stearic acid, magnesium stearate, silicon dioxide, and food glaze containing protein: ad 100 g 	<p>[^{F1}2106 90 92]</p>	<p>Classification is determined by the provisions of general rules 1 and 6 for the interpretation of the combined nomenclature and the texts of CN codes 2106, 2106 90 and [^{F1}2106 90 92]. The product is a food supplement (see also HS Explanatory [^{F2}Note to heading 21.06])</p>
<p>3. Preparation in the form of tablets put up in packings for retail sale with instructions on dosage and composition to counter deficiency resulting from the menstruation of women.</p> <p>Composition per 100 g of the preparation:</p> <ul style="list-style-type: none"> — Oil of evening primrose: 11,4 g — Vitamin B6: 6,8 g — Magnesium oxide: 5,7 g — Calcium carbonate: 2,9 g — Herbal mixture: 2,4 g — Potassium gluconate: 2,3 g — Folic acid: 0,009 g 	<p>[^{F1}2106 90 92]</p>	<p>Classification is determined by the provisions of general rules 1 and 6 for the interpretation of the combined nomenclature and the texts of CN codes 2106, 2106 90 and [^{F1}2106 90 92]. The product is a food supplement (see also HS code Explanatory [^{F2}Note to heading 21.06])</p>

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EEC) No 2061/89. (See end of Document for details)

<p>— Cellulose, stearic acid, magnesium stearate, silicon dioxide and food glaze containing protein: ad 100 g</p>		
<p>4. Preparation in the form of tablets put up in packings for retail sale with instructions on dosage and composition, to ensure a balance of substances contained in hair.</p> <p>Each tablet of approximately 2g contains:</p> <p>— Biotin: 500 µg</p> <p>— L-Cysteine: 150 mg</p> <p>— Choline bitartrate: 125 mg</p> <p>— Inositol: 62,5 mg</p> <p>— Vitamin B12: 12,5 µg</p> <p>— Folic acid: 400 µg</p> <p>— Ascorbic acid: 150 mg</p> <p>— Manganese gluconate: 5 mg</p> <p>— Para aminobenzoic acid: 37,5 mg</p> <p>— Niacinamide: 15 mg</p> <p>— Pantothenic acid: 50 mg</p> <p>— Vitamin B6: 37,5 mg</p> <p>— Zinc gluconate: 15 mg</p> <p>— Ferrous gluconate: 10 mg</p> <p>— Iodine: 75 µg</p> <p>— Copper gluconate: 1 mg</p> <p>— Millet extract: 200 mg</p> <p>In a base containing: Beta carotene, aloe vera, amino acids, cellulose, stearic acid and food glaze containing protein</p>	<p>[^{F1}2106 90 92]</p>	<p>Classification is determined by the provisions of general rules 1 and 6 for the interpretation of the combined nomenclature and the texts of CN codes 2106, 2106 90 and [^{F1}2106 90 92]. The product is a food supplement (see also HS Explanatory [^{F2}Note to heading 21.06])</p>

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EEC) No 2061/89. (See end of Document for details)

<p>[^{F3}5. Preparation in the form of tablets put up in packages for retail sale with instructions on dosage and composition, to counter deficiency in vitamin C.</p> <p>Each tablet weighing 750 mg contains:</p> <p>— Ascorbic acid: 500 mg</p> <p>— Rose hip powder, cellulose, vegetable stearine, botanical oil solids, magnesium stearate, silicon dioxide and food glaze containing protein: 250 mg.</p>	<p>[^{F2}3004 50 00]</p>	<p>Classification is determined by General Rules 1 and 6 for the interpretation of the combined nomenclature, Additional Note 1 to Chapter 30 and by the wording of the CN codes 3004, 3004 50 and [^{F2}3004 50 00].</p> <p>See also the Combined Nomenclature Explanatory Notes to Chapter 30 (General).</p> <p>As regards the recommended daily allowance (RDA) for vitamin C (60 mg), each tablet clearly contains a much higher amount of vitamin C (500 mg).</p> <p>All conditions of Additional Note 1 to Chapter 30 are therefore met and the product is to be classified as a medicament of Heading 3004.]</p>
<p>6. Injectable preparation, sterile, pyrogen-free, consisting of purified collagen dispersed in a phosphate physiological saline buffered solution, whether or not containing lidocaine (INN), put up for retail sale</p>	<p>[^{F2}3004 90 00]</p>	<p>Classification is determined by the provisions of general rules 1 and 6 for the interpretation of the combined nomenclature and the texts of CN codes 3004, 3004 90 and [^{F2}3004 90 00].</p> <p>This product is used in the treatment of atrophy due to disease, trauma or other disorders of the conjunctive tissue</p>

Textual Amendments

- F1** Substituted by [Commission Regulation \(EC\) No 936/1999 of 27 April 1999 amending or repealing certain regulations on the classification of goods in the Combined Nomenclature.](#)
- F2** Substituted by [Commission Implementing Regulation \(EU\) No 441/2013 of 7 May 2013 amending or repealing certain regulations on the classification of goods in the Combined Nomenclature.](#)
- F3** Substituted by [Commission Regulation \(EC\) No 1966/2005 of 1 December 2005 amending Regulation \(EEC\) No 2061/89 concerning the classification of certain goods in the Combined Nomenclature.](#)

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EEC) No 2061/89. (See end of Document for details)

- (1) OJ No L 256, 7. 9. 1987, p. 1.
- (2) OJ No L 169, 19. 6. 1989, p. 1.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EEC) No 2061/89.